ClinicalTrials.gg
CompletedNCT01294527WiSE-CRTUpdated Feb 8, 2017

Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy

An interventional study of Wireless cardiac stimulator implant to pace the left ventricle for CRT in Heart Failure, Ventricular Dysfunction and Cardiomyopathy, sponsored by EBR Systems, Inc.. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by EBR Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.

Enrollment
345th of 386
17 · median 161
Started
2011
with 27 others
No phase
175 of 600
37 open now
Registered
147th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 345th largest by enrollment of the 386 interventional ones that give a count, is one of 28 that started in 2011, is one of 175 with no phase, and was the 147th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

100 more — sign in →

All 105 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

The WiCS-LV system is an alternative means to providing left ventricular stimulation for Cardiac Resynchronization Therapy (CRT). The purpose of this study is to evaluate the safety and performance of the WiCS-LV System in patients with indications for CRT.

Read the detailed description

Eligible patients will undergo an acoustic window assessment using transthoracic echocardiography. Patients with adequate acoustic windows will undergo implantation of the WiCS-LV system.

Patients will undergo evaluations pre-hospital discharge, and at one month, 3 months, and 6 months post implantation. Extended follow-up will be obtained via a registry at 1, 2, 3, 4, and 5 years post implantation.

03

Conditions studied

  • Heart Failure
  • Ventricular Dysfunction
  • Cardiomyopathy

Keywords

  • Cardiac Resynchronization Therapy
  • cardiac pacing
  • electrical stimulation
  • bi-ventricular pacing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with standard indication for CRT based upon the most recent guidelines AND meeting criteria for one of these three categories:

  1. Patients with previously implanted pacemakers or ICD's and meeting standard indications for CRT - referred to as "upgrades"
  2. Patients in whom attempted coronary sinus lead implantation for CRT has failed - referred to as "untreated"
  3. Patients with previously implanted CRT device, not responding to CRT (no change or worsening of symptom or functional class after 6 months of treatment confirmed by investigator) - referred to as "non-responders"

Exclusion criteria

Exclusion Criteria:

  1. Inability to comply with the study follow-up or other study requirements
  2. to heparin
  3. Contraindication to both chronic anticoagulants and antiplatelet agents
  4. Contraindication to iodinated contrast agents
  5. Intracardiac thrombus by transesophageal echocardiography
  6. Age less than 18 years
  7. Attempted IPG implant within 3 days
  8. of \< 12 months
  9. Chronic hemodialysis
  10. Myocardial infarction within one month
  11. Major cardiac surgery within one month
  12. Female of , pregnant, or breastfeeding
  13. Noncardiac implanted electrical stimulation therapy devices
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Implant

    Implant of the WiCS-LV system

    Device: Wireless cardiac stimulator implant to pace the left ventricle for CRT

Interventions

  • DeviceWireless cardiac stimulator implant to pace the left ventricle for CRT

    Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator

    Also known as: WiCS-LV system

06

What researchers measure

Primary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

    Time frame: 24 hour peri-operative and one month

  2. Number of patients with procedure-related adverse events as a measure of safety

    Procedure-related adverse events are those which occur during the WiCS-LV system implant procedure.

    Time frame: 24 hour perioperative and one month

  3. Bi-ventricular pacing capture

    Bi-ventricular pacing capture documented on 12-lead EKG

    Time frame: one month

Secondary outcomes

  1. Number of patients with device-related adverse events as a measure of safety

    Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.

    Time frame: 6 months

  2. Number of patients with serious adverse events as a measure of safety

    Time frame: 6 months

  3. Left ventricular pacing capture

    Left ventricular pacing capture documented on 12-lead EKG

    Time frame: 1, 3, and 6 months

  4. Bi-ventricular pacing capture

    Bi-ventricular pacing capture documented on 12-lead EKG

    Time frame: 3 and 6 months

  5. Bi-ventricular pacing capture

    Bi-ventricular pacing capture on 24 hour ambulatory monitoring

    Time frame: 1, 3, and 6 months

  6. Clinical composite score

    Composite of all cause mortality, heart failure hospitalization, NYHA class, and patient global assessment

    Time frame: 6 months

  7. Change in echocardiographic indices

    change in left-ventricular end-systolic volume, left ventricular end-diastolic volume, and ejection fraction

    Time frame: 6 months

  8. Change in blood laboratory Brain Natriuretic Peptide

    change in NT-proBNP level

    Time frame: 6 months

07

Study locations

10 sites
  • Nouvelles Clinicques Nantaises
    Nantes, France
  • Hospital Pontchaillou-CHU
    Rennes, France
  • Kerckhoff-Klinik
    Bad Nauheim, Germany
  • Herzzentrum Brandenburg
    Bernau, Germany
  • Klinium Coburg gGmbH
    Coburg, Germany
  • Facharztzentrum Dresden-Neustadt GbR
    Dresden, Germany
  • Herzzentrum Leipzig GmbH
    Leipzig, Germany
  • Leiden University Medical Centre
    Leiden, Netherlands
  • Isala Klinieken Zwolle
    Zwolle, Netherlands
  • Cardiocentro Ticini
    Lugano, Switzerland
08

References and documents

Publications

  • Auricchio A, Delnoy PP, Butter C, Brachmann J, Van Erven L, Spitzer S, Moccetti T, Seifert M, Markou T, Laszo K, Regoli F; Collaborative Study Group. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Europace. 2014 May;16(5):681-8. doi: 10.1093/europace/eut435. Epub 2014 Feb 4. PubMed 24497573 ↗
  • Auricchio A, Delnoy PP, Regoli F, Seifert M, Markou T, Butter C; collaborative study group. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace. 2013 Aug;15(8):1191-7. doi: 10.1093/europace/eut124. Epub 2013 May 23. PubMed 23703364 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2012 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2011
First posted
Feb 11, 2011
Start
Feb 2011
Primary completionActual
Apr 2012
CompletionActual
Oct 2016
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01294527
Lead sponsor
EBR Systems, Inc.
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Feb 2011
Primary completion
Apr 2012
Completion
Oct 2016
Last update
Feb 8, 2017

Study contacts

Angelo Auricchio, MD
principal investigator · Fondazione Cardiocentro, Lugano CH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion